Belzutifan
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BELZUTIFAN |
|---|---|
| Type | Drug |
| Aliases | WeliregБелзутифан |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-RCC |
| Sources | SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Drug Facts
| Class | HIF-2α inhibitor |
|---|---|
| Mechanism | Selective small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). VHL inactivation (somatic in ~90% of clear-cell RCC, germline in von Hippel-Lindau syndrome) → HIF-2α stabilization → drives the angiogenic/glycolytic ccRCC phenotype. Belzutifan disrupts HIF-2α heterodimerization with HIF-1β, suppressing the downstream transcriptional programme. |
| Typical dosing | 120 mg PO once daily, continuous, until progression or unacceptable toxicity. Hemoglobin and oxygen-saturation monitoring at baseline + every cycle — anemia + hypoxia are class-defining ON-target effects (HIF-2α regulates EPO). |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
First-in-class HIF-2α inhibitor; mechanism-of-action drug for VHL-syndrome-associated tumors. In sporadic ccRCC, used 2L+ after PD-(L)1 + VEGF-TKI. Reduces hemangioblastoma volume and pancreatic NET volume in VHL syndrome — surgery-sparing in many cases. UA-access is the bottleneck; document pathway in AccessPathway entity once Phase D content lands.
Used By
Regimens
REG-BELZUTIFAN-MONO- Belzutifan monotherapy (VHL-disease tumors / mRCC 2L+)